JEZ-567 is under clinical development by Novartis and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback